scholarly journals Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension

2020 ◽  
Vol 115 (6) ◽  
Author(s):  
Max-Paul Winter ◽  
Smriti Sharma ◽  
Johanna Altmann ◽  
Veronika Seidl ◽  
Adelheid Panzenböck ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Pulmonary Hypertension ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Vascular Endothelial Growth Factor Receptor 3 Signaling Contributes to Angioobliterative Pulmonary Hypertension

2015 ◽  
Vol 5 (1) ◽  
pp. 101-116 ◽  
Author(s):  
Ayser Al-Husseini ◽  
Donatas Kraskauskas ◽  
Eleanora Mezzaroma ◽  
Andrea Nordio ◽  
Daniela Farkas ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Pulmonary Hypertension ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document